Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals – Carrier is inorganic
Reexamination Certificate
2007-06-12
2007-06-12
Angell, Jon E. (Department: 1635)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
Carrier is inorganic
C436S518000
Reexamination Certificate
active
10093578
ABSTRACT:
The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.
REFERENCES:
patent: 2768958 (1956-10-01), Stewart et al.
patent: 2785153 (1957-03-01), Locke et al.
patent: 3145144 (1964-08-01), Ando et al.
patent: 3149036 (1964-09-01), Woodhour et al.
patent: 3269912 (1966-08-01), Grafe
patent: 3399263 (1968-08-01), Strazdins et al.
patent: 3531565 (1970-09-01), Webb et al.
patent: 3577523 (1971-05-01), Stolar et al.
patent: 3651211 (1972-03-01), Gillchriest et al.
patent: 3819820 (1974-06-01), Lorina et al.
patent: 3919413 (1975-11-01), Mebus
patent: 3983228 (1976-09-01), Woodhour et al.
patent: 4016252 (1977-04-01), Relyveld
patent: 4053587 (1977-10-01), Davidson et al.
patent: 4069313 (1978-01-01), Woodhour et al.
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 4196185 (1980-04-01), Focella et al.
patent: 4197237 (1980-04-01), Leute et al.
patent: 4197286 (1980-04-01), Rao
patent: 4213964 (1980-07-01), Buckler
patent: 4215036 (1980-07-01), Malley
patent: 4218436 (1980-08-01), Fitzpatrick
patent: 4329281 (1982-05-01), Christenson et al.
patent: 4330530 (1982-05-01), Baker
patent: 4332787 (1982-06-01), Homcy et al.
patent: 4339437 (1982-07-01), Rosenberg et al.
patent: 4346074 (1982-08-01), Gilmour et al.
patent: 4451570 (1984-05-01), Royston et al.
patent: 4487780 (1984-12-01), Scheinberg
patent: 4578270 (1986-03-01), Csizer et al.
patent: 4594325 (1986-06-01), Lundak
patent: 4608252 (1986-08-01), Khanna et al.
patent: 4624921 (1986-11-01), Larrick et al.
patent: 4624923 (1986-11-01), Margel
patent: 4639336 (1987-01-01), Jouquey et al.
patent: 4657763 (1987-04-01), Finkelstein
patent: 4693975 (1987-09-01), Kozbor et al.
patent: 4710378 (1987-12-01), Ohtomo et al.
patent: 4720459 (1988-01-01), Winkelhake
patent: 4740589 (1988-04-01), Moreno
patent: 4744760 (1988-05-01), Molday
patent: 4753873 (1988-06-01), Beltz et al.
patent: 4812556 (1989-03-01), Vahlne et al.
patent: 4880750 (1989-11-01), Francoeur
patent: 4882423 (1989-11-01), Taguchi et al.
patent: 4906564 (1990-03-01), Lyon et al.
patent: 4977286 (1990-12-01), Nicolaou et al.
patent: 5017687 (1991-05-01), Vahlne et al.
patent: 5019497 (1991-05-01), Olsson
patent: 5035995 (1991-07-01), Taguchi et al.
patent: 5112606 (1992-05-01), Shiosaka et al.
patent: 5126253 (1992-06-01), Nakanishi et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5686578 (1997-11-01), Goldenberg
patent: 6274552 (2001-08-01), Tamarkin et al.
patent: 6528485 (2003-03-01), Veronese et al.
patent: 2004/0018203 (2004-01-01), Pastan et al.
patent: 0 044 722 (1982-01-01), None
patent: 0 179 483 (1986-04-01), None
patent: 0 269 408 (1987-11-01), None
patent: 0 486 526 (1991-02-01), None
patent: 0 667 398 (1995-08-01), None
patent: 2 334 366 (1977-08-01), None
patent: 2 533 827 (1984-04-01), None
patent: 981242 (1965-01-01), None
patent: WO 94/21288 (1994-09-01), None
patent: WO 99/24077 (1999-05-01), None
Balkwill, et al. “The Cytokline Network”,Immunology Today, vol. 10, No. 9, pp. 299-304 (1989).
Coulombe, et al., “Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chlorphrntermine-induced Phospholipidosis,”Journal of Histochemistry and Cytochemistry, vol. 37, No. 2, pp. 129-147 (1989).
Fraker, et al., “Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity”,The Journal of Experimental Medicine, vol. 170, pp. 1015-1020 (1989).
Goldstein, et al., “Cardiovascular Effects of Platelet-Activating Factor,”Lipids, vol. 26, No. 12, pp. 1250-1256 (1991).
Hashimoto, et al., “Action Site of Circulating Interleukin-1 on the Rabbit Brain”,Brain Research, vol. 540, pp. 217-223 (1991).
Hisamatsu, et al., “Platelet Activating Factor Induced-Respiratory Mucosal Damage,”Lipids, vol. 26, No. 12, pp. 1287-1291 (1991).
Hopkins, et al., “Early Events Following the Binding Epidermal Growth Factor to Surface Receptors on Ovarian Granulosa Cells,”European Journal of Cell Biology, vol. 24, pp. 259-265 (1981).
Kang, et al., “Ultrastructural and Immunocytochemical Study of the Uptake and Distribution of Bacterial Lipopolysaccharide in Human Monocytes,”Journal of Leukocyte Biology, vol. 48, pp. 316-332 (1990).
Kirchner, t al., “The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2,”Cancer, vol. 67, pp. 1862-1864 (1991).
Lanzavecchia, “Identifying Strategies for Immune Intervention,”Science, vol. 260, pp. 937-944 (1993).
Morris, et al., “Validation of the Biotinyl Ligand-Avidin-Gold Technique,”The Journal of Histochemistry and Cytochemistry, vol. 40, No. 5, pp. 711-721 (1992).
Ohmann, et al., “Expression of Tumor Necrosis Factor-a Receptors on bovine Macrophaes, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects,”Lymphokine Research, vol. 9, No. 1, pp. 43-58 (19900.
Paciotti, et al., “Interleukin-1α Differentially Synchronizes Estrogen-Dependent and Estrogen-Independent Human Breast Cancer Cells in the Go/G1Phase of the Cell Cycle,”Anticancer Research, vol. 11, pp. 25-32 (1991).
Paciotti, et al., “Interleukin-1 Directly Regulates Hormone-Dependent-Human Breast Cancer Cell Proliferationin Vitro,” Molecular Endocrinology, vol. 2, No. 5, pp. 459-464 (1988).
Paciotti, et al, “Interleukin-2 Differentially Affects the Proliferation of a Hormone-Dependent and a Hormone-Independent Human Breast Cancer Cell Line In Vitro and In Vivo,”Anticancer Research, vol. 8, pp. 1233-1240 (1988).
Peters, et al., “Binding and Internalization of Biotinylated Interleukin-2 in Human Lymphocytes,”Blood, vol. 76, No. 1, pp. 97-104 (19900.
Roitt, et al.,Immunology, Mosby, (Baltimore, MD) 3rded., p. 8.15. (19930.
Tommi, et al., “Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Carrier,”,Jpn. J. Med. Sci. Biol., vol. 44, pp. 75-80 (1991).
Paciotti Giulio F.
Tamarkin Lawrence
Angell Jon E.
Cytimmune Sciences, Inc.
King & Spalding LLP
LandOfFree
Colloidal metal compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Colloidal metal compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Colloidal metal compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3844780